Quantum spin liquid state in a two-dimensional semiconductive metal–organic framework

Y Misumi, A Yamaguchi, Z Zhang… - Journal of the …, 2020 - ACS Publications
Two-dimensional metal–organic frameworks (2D MOFs) have attracted much attention, as
they are the crystalline materials that exhibit both conductivity and microporosity. Numerous …

[HTML][HTML] Prospective evaluation of the G8 screening tool for prognostication of survival in elderly patients with lung cancer: a single-institution study

…, T Shimokawa, J Sasaki, K Miyazaki, Y Misumi… - PLoS …, 2019 - journals.plos.org
The G8 questionnaire is a quick and easy-to-use screening tool. Several studies reported
that the G8 questionnaire had a high sensitivity for predicting abnormalities in the full …

[HTML][HTML] First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in …

…, M Maemondo, K Minato, T Hisada, Y Misumi… - International journal of …, 2022 - Springer
Background CheckMate 9LA, a phase 3, randomized, open-label study in first-line advanced
non-small cell lung cancer (NSCLC), showed significantly improved overall survival (OS) …

[HTML][HTML] Acute pancreatitis or severe increase in pancreatic enzyme levels following remdesivir administration in COVID-19 patients: an observational study

…, M Aga, Y Hamakawa, Y Taniguchi, Y Misumi… - Scientific Reports, 2022 - nature.com
Remdesivir has been shown to reduce recovery time and mortality among patients with
coronavirus disease 2019 (COVID-19). However, data regarding the efficacy and safety of …

[HTML][HTML] Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study

…, M Aga, Y Hamakawa, Y Taniguchi, Y Misumi… - BMC cancer, 2022 - Springer
Background Granulocyte colony-stimulating factor (G-CSF)-producing lung cancer induces
severe inflammation and a high white blood cell (WBC) count and is associated with poor …

[HTML][HTML] Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase …

T Shimokawa, H Okamoto, R Machida, Y Misumi… - Lung Cancer, 2023 - Elsevier
Objectives Cisplatin plus irinotecan has been considered as the standard therapy in younger
(<70 years old) patients for extensive-disease small-cell lung cancer (ED-SCLC) in Japan. …

[HTML][HTML] Association of PD‐L1 tumor proportion score ≥20% with early resistance to osimertinib in patients with EGFR‐mutated NSCLC

…, M Aga, K Miyazaki, Y Taniguchi, Y Misumi… - Cancer …, 2023 - Wiley Online Library
Background The relationship between epidermal growth factor receptor tyrosine kinase inhibitor
(EGFR‐TKI) resistance, including osimertinib, and programmed cell death‐ligand 1 (PD‐…

Phase II Study of Durvalumab Immediately after Completion of Chemoradiotherapy in Unresectable Stage III Non–small Cell Lung Cancer: TORG1937 (DATE Study)

S Nakamichi, K Kubota, T Misumi, T Kondo… - Clinical Cancer …, 2024 - AACR
Purpose: Concurrent chemoradiotherapy (CCRT) followed by durvalumab consolidation for
up to 12 months is the standard of care for patients with unresectable stage III non–small cell …

[HTML][HTML] Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non …

N Aiko, T Shimokawa, K Miyazaki, Y Misumi, Y Agemi… - BMC cancer, 2018 - Springer
Background Compared with standard chemotherapy, epidermal growth factor receptor
tyrosine kinase inhibitors (EGFR-TKIs) are more effective in patients with advanced non-small-cell …

A phase II study of durvalumab (MEDI4736) immediately after completion of chemoradiotherapy in unresectable stage III non–small cell lung cancer: TORG1937 …

S Nakamichi, K Kubota, T Misumi, S Murakami… - 2022 - ascopubs.org
8536 Background: Concurrent chemoradiotherapy followed by durvalumab maintenance for
up to 12 months is the standard of care for patients with unresectable stage III non-small cell …